Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013, 48193-48197 [2013-19046]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices
To submit
comments:
Send them to:
By e-mail ......
pubcommentees.enrd@usdoj.gov.
Assistant Attorney General,
U.S. DOJ—ENRD, P.O.
Box 7611, Washington, DC
20044–7611.
By mail .........
Under section 7003(d) of RCRA, a
commenter may request an opportunity
for a public meeting in the affected area.
During the public comment period,
the Consent Decree may be examined
and downloaded at this Justice
Department Web site: https://
www.usdoj.gov/enrd/
Consent_Decrees.html. We will provide
a paper copy of the Consent Decree
upon written request and payment of
reproduction costs. Please mail your
request and payment to: Consent Decree
Library, U.S. DOJ—ENRD, P.O. Box
7611, Washington, DC 20044–7611.
Please enclose a check or money order
for $8.25 (25 cents per page
reproduction cost) payable to the United
States Treasury.
Maureen M. Katz,
Assistant Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 2013–19005 Filed 8–6–13; 8:45 am]
BILLING CODE 4410–15–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–365]
Final Adjusted Aggregate Production
Quotas for Schedule I and II Controlled
Substances and Assessment of
Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2013
Drug Enforcement
Administration (DEA), Department of
Justice.
ACTION: Notice.
AGENCY:
This notice establishes final
adjusted 2013 aggregate production
quotas for controlled substances in
Schedules I and II of the Controlled
Substances Act (CSA) and assessment of
annual needs for the List I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, as well as the
2013 aggregate production quotas for
three recently temporarily controlled
substances.
FOR FURTHER INFORMATION CONTACT: John
W. Partridge, Executive Assistant, Office
of Diversion Control, Drug Enforcement
Administration, 8701 Morrissette Drive,
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:03 Aug 06, 2013
Jkt 229001
Springfield, VA 22152, Telephone: (202)
307–7165.
SUPPLEMENTARY INFORMATION:
Background
Section 306 of the CSA (21 U.S.C.
826) requires the Attorney General to
establish aggregate production quotas
for each basic class of controlled
substance listed in Schedules I and II
and for ephedrine, pseudoephedrine,
and phenylpropanolamine. This
responsibility has been delegated to the
Administrator of the DEA through 28
CFR 0.100. The Administrator, in turn,
has redelegated this function to the
Deputy Administrator, pursuant to 28
CFR 0.104. DEA published the 2013
established aggregate production quotas
for controlled substances in Schedules I
and II and assessment of annual needs
for the List I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine in the Federal
Register (77 FR 59980) on October 1,
2012. That notice stated that the Deputy
Administrator would adjust, as needed,
the established aggregate production
quotas in 2013 as provided for in 21
CFR 1303.13 and 21 CFR 1315.13. The
2013 proposed adjusted aggregate
production quotas for controlled
substances in Schedules I and II and
assessment of annual needs for the List
I chemicals ephedrine,
pseudoephedrine, and
phenylpropanolamine were
subsequently published in the Federal
Register on June 20, 2013, (78 FR 37237)
in consideration of the outlined criteria.
All interested persons were invited to
comment on or object to the proposed
adjusted aggregate production quotas
and assessment of annual needs on or
before July 22, 2013.
Analysis for Final Adjusted 2013
Aggregate Production Quotas and
Assessment of Annual Needs
Consideration has been given to the
criteria outlined in the June 20, 2013,
notice of proposed adjusted aggregate
production quotas and assessment of
annual needs, in accordance with 21
CFR 1303.13 and 21 CFR 1315.13. Six
companies submitted timely comments
regarding a total of 30 Schedule I and II
controlled substances. Comments
received proposed that the aggregate
production quotas for 2-(2,5-Dimethoxy4-(n)-propylphenyl)ethanamine (2C–P);
2-(2,5-Dimethoxy-4ethylphenyl)ethanamine (2C–E); 2-(2,5Dimethoxy-4-methylphenyl)ethanamine
(2C–D); 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C–N); 2-(2,5Dimethoxyphenyl)ethanamine (2C–H);
2-(4-Chloro-2,5dimethoxyphenyl)ethanamine (2C–C);
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
48193
2-(4-Iodo-2,5dimethoxyphenyl)ethanamine (2C–I); 2[4-(Ethylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–2);
2-[4-(Isopropylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–4);
3,4-Methylenedioxymethamphetamine
(MDMA); 4-Anilino-N-phenethyl-4piperidine (ANPP); amphetamine (for
sale); codeine (for conversion);
dihydromorphine; diphenoxylate (for
sale); gamma hydroxybutyric acid;
hydrocodone; hydromorphone;
levomethorphan; methadone;
methadone intermediate;
methylphenidate; morphine (for
conversion); morphine (for sale);
oxycodone (for sale); oripavine;
oxymorphone (for conversion);
oxymorphone (for sale); phenylacetone;
and sufentanil were insufficient to
provide for the estimated medical,
scientific, research, and industrial needs
of the United States, for export
requirements, and for the establishment
and maintenance of reserve stocks. One
manufacturer commented that the APQ
for thebaine was insufficient; however,
that commenter was referring to a need
for procurement quota for thebaine,
which does not directly impact the APQ
and, thus, was not considered. DEA did
not previously propose adjustments to
the 2013 assessment of annual needs for
ephedrine, pseudoephedrine, and
phenylpropanolamine and received no
comments concerning such.
DEA has taken into consideration the
above comments along with the relevant
2012 year-end inventories, initial 2013
manufacturing quotas and import
quotas, 2013 export requirements, actual
and projected 2013 sales, research and
product development requirements, and
additional applications received. Based
on all of the above, the Deputy
Administrator has determined that the
proposed adjusted 2013 aggregate
production quotas and assessment of
annual needs for dihydromorphine;
diphenoxylate (for sale); gamma
hydroxybutyric acid; hydromorphone;
levomethorphan; morphine (for sale);
oxymorphone (for sale); phenylacetone;
psilocyn; sufentanil; ephedrine (for
sale); phenylpropanolamine (for
conversion); and pseudoephedrine (for
sale) required additional consideration
and hereby further adjusts the 2013
aggregate production quotas for those
substances.
Regarding 2-(2,5-Dimethoxy-4-(n)propylphenyl)ethanamine (2C–P); 2(2,5-Dimethoxy-4ethylphenyl)ethanamine (2C–E); 2-(2,5Dimethoxy-4-methylphenyl)ethanamine
(2C–D); 2-(2,5-Dimethoxy-4-nitrophenyl)ethanamine (2C–N); 2-(2,5Dimethoxyphenyl)ethanamine (2C–H);
E:\FR\FM\07AUN1.SGM
07AUN1
48194
Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices
2-(4-Chloro-2,5dimethoxyphenyl)ethanamine (2C–C);
2-(4-Iodo-2,5dimethoxyphenyl)ethanamine (2C–I); 2[4-(Ethylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–2);
2-[4-(Isopropylthio)-2,5dimethoxyphenyl]ethanamine (2C–T–4);
3,4-Methylenedioxymethamphetamine
(MDMA); 4-Anilino-N-phenethyl-4piperidine (ANPP); amphetamine (for
sale); codeine (for conversion);
hydrocodone; methadone; methadone
intermediate; methylphenidate;
morphine (for conversion); oxycodone
(for sale); oripavine; and oxymorphone
(for conversion), the Deputy
Administrator hereby determines that
the proposed adjusted 2013 aggregate
production quotas and assessment of
annual needs for these substances and
List I chemicals as published on June
20, 2013, (78 FR 37237) are sufficient to
meet the current 2013 estimated
medical, scientific, research, and
industrial needs of the United States
and to provide for adequate inventories.
As described in the previously
published notice establishing the 2013
aggregate production quotas and
assessment of annual needs, DEA has
specifically considered that inventory
allowances granted to individual
manufacturers may not always result in
the availability of sufficient quantities to
maintain an adequate reserve stock
pursuant to 21 U.S.C. 826(a), as
intended. See 21 CFR 1303.24. This
would be concerning if a natural
disaster or other unforeseen event
resulted in substantial disruption to the
amount of controlled substances
available to provide for legitimate
public need. As such, DEA has included
in all proposed revised Schedule II
aggregate production quotas, and certain
Schedule I aggregate production quotas,
an additional 25% of the estimated
medical, scientific, and research needs
as part of the amount necessary to
ensure the establishment and
maintenance of reserve stocks. The
resulting adjusted established aggregate
production quotas will reflect these
included amounts. This action will not
affect the ability of manufacturers to
maintain inventory allowances as
specified by regulation. DEA expects
that maintaining this reserve in certain
established aggregate production quotas
will mitigate adverse public effects if an
unforeseen event resulted in substantial
disruption to the amount of controlled
substances available to provide for
legitimate public need, as determined
by DEA. DEA does not anticipate
utilizing the reserve in the absence of
these circumstances.
Pursuant to the above, the Deputy
Administrator hereby finalizes the 2013
aggregate production quotas for the
following Schedule I and II controlled
substances and the 2013 assessment of
annual needs for the List I chemicals
ephedrine, pseudoephedrine, and
phenylpropanolamine, expressed in
grams of anhydrous acid or base, as
follows:
Final adjusted
2013 quotas
Basic class
Temporarily Scheduled Substances
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR–144) ...............................................................................
[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (XLR11) ..................................................................
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (AKB48) .....................................................................................................
15 g
15 g
15 g
mstockstill on DSK4VPTVN1PROD with NOTICES
Schedule I
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) ........................................................................................................................
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) .......................................................................................................................
1-[1-(2-Thienyl)cyclohexyl]piperidine ...............................................................................................................................................
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH–200) ..........................................................................................................
1-Butyl-3-(1-naphthoyl)indole (JWH–073) .......................................................................................................................................
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR–18 and RCS–8) .....................................................................................
1-Hexyl-3-(1-naphthoyl)indole (JWH–019) ......................................................................................................................................
1-Methyl-4-phenyl-4-propionoxypiperidine .......................................................................................................................................
1-Pentyl-3-(1-naphthoyl)indole (JWH–018 and AM678) .................................................................................................................
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH–203) .......................................................................................................................
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH–250) ...................................................................................................................
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH–398) .......................................................................................................................
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH–122) ......................................................................................................................
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR–19, RCS–4) ...............................................................................................................
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH–081) ..................................................................................................................
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C–P) ..............................................................................................................
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E) ......................................................................................................................
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D) ...................................................................................................................
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N) .....................................................................................................................
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H) ..................................................................................................................................
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C) ....................................................................................................................
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I) .........................................................................................................................
2,5-Dimethoxy-4-ethylamphetamine (DOET) ..................................................................................................................................
2,5-Dimethoxy-4-n-propylthiophenethylamine .................................................................................................................................
2,5-Dimethoxyamphetamine ............................................................................................................................................................
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2) ...........................................................................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4) ....................................................................................................
3,4,5-Trimethoxyamphetamine ........................................................................................................................................................
3,4-Methylenedioxyamphetamine (MDA) ........................................................................................................................................
3,4-Methylenedioxymethamphetamine (MDMA) .............................................................................................................................
3,4-Methylenedioxy-N-ethylamphetamine (MDEA) .........................................................................................................................
3,4-Methylenedioxy-N-methylcathinone (methylone) ......................................................................................................................
3,4-Methylenedioxypyrovalerone (MDPV) .......................................................................................................................................
3-Methylfentanyl ...............................................................................................................................................................................
3-Methylthiofentanyl .........................................................................................................................................................................
VerDate Mar<15>2010
17:03 Aug 06, 2013
Jkt 229001
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
45
45
5
45
45
45
45
2
45
45
45
45
45
45
45
15
15
15
15
15
15
15
12
12
12
15
15
12
30
50
24
35
25
2
2
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices
Final adjusted
2013 quotas
Basic class
mstockstill on DSK4VPTVN1PROD with NOTICES
48195
4-Bromo-2,5-dimethoxyamphetamine (DOB) ..................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine (2–CB) .............................................................................................................................
4-Methoxyamphetamine ..................................................................................................................................................................
4-Methyl-2,5-dimethoxyamphetamine (DOM) ..................................................................................................................................
4-Methylaminorex ............................................................................................................................................................................
4-Methyl-N-methylcathinone (mephedrone) ....................................................................................................................................
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol .....................................................................................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47, 497 C8-homolog) .....................
5-Methoxy-3,4-methylenedioxyamphetamine ..................................................................................................................................
5-Methoxy-N,N-diisopropyltryptamine ..............................................................................................................................................
5-Methoxy-N,N-dimethyltryptamine .................................................................................................................................................
Acetyl-alpha-methylfentanyl .............................................................................................................................................................
Acetyldihydrocodeine .......................................................................................................................................................................
Acetylmethadol ................................................................................................................................................................................
Allylprodine ......................................................................................................................................................................................
Alphacetylmethadol ..........................................................................................................................................................................
Alpha-ethyltryptamine ......................................................................................................................................................................
Alphameprodine ...............................................................................................................................................................................
Alphamethadol .................................................................................................................................................................................
Alpha-methylfentanyl .......................................................................................................................................................................
Alpha-methylthiofentanyl ..................................................................................................................................................................
Alpha-methyltryptamine (AMT) ........................................................................................................................................................
Aminorex ..........................................................................................................................................................................................
Benzylmorphine ...............................................................................................................................................................................
Betacetylmethadol ...........................................................................................................................................................................
Beta-hydroxy-3-methylfentanyl ........................................................................................................................................................
Beta-hydroxyfentanyl .......................................................................................................................................................................
Betameprodine .................................................................................................................................................................................
Betamethadol ...................................................................................................................................................................................
Betaprodine ......................................................................................................................................................................................
Bufotenine ........................................................................................................................................................................................
Cathinone .........................................................................................................................................................................................
Codeine-N-oxide ..............................................................................................................................................................................
Desomorphine ..................................................................................................................................................................................
Diethyltryptamine .............................................................................................................................................................................
Difenoxin ..........................................................................................................................................................................................
Dihydromorphine ..............................................................................................................................................................................
Dimethyltryptamine ..........................................................................................................................................................................
Gamma-hydroxybutyric acid ............................................................................................................................................................
Heroin ..............................................................................................................................................................................................
Hydromorphinol ................................................................................................................................................................................
Hydroxypethidine .............................................................................................................................................................................
Ibogaine ...........................................................................................................................................................................................
Lysergic acid diethylamide (LSD) ....................................................................................................................................................
Marihuana ........................................................................................................................................................................................
Mescaline .........................................................................................................................................................................................
Methaqualone ..................................................................................................................................................................................
Methcathinone .................................................................................................................................................................................
Methyldihydromorphine ....................................................................................................................................................................
Morphine-N-oxide ............................................................................................................................................................................
N,N-Dimethylamphetamine ..............................................................................................................................................................
N-Benzylpiperazine ..........................................................................................................................................................................
N-Ethylamphetamine .......................................................................................................................................................................
N-Hydroxy-3,4-methylenedioxyamphetamine ..................................................................................................................................
Noracymethadol ...............................................................................................................................................................................
Norlevorphanol .................................................................................................................................................................................
Normethadone .................................................................................................................................................................................
Normorphine ....................................................................................................................................................................................
Para-fluorofentanyl ...........................................................................................................................................................................
Phenomorphan ................................................................................................................................................................................
Pholcodine .......................................................................................................................................................................................
Properidine .......................................................................................................................................................................................
Psilocybin .........................................................................................................................................................................................
Psilocyn ............................................................................................................................................................................................
Tetrahydrocannabinols ....................................................................................................................................................................
Thiofentanyl .....................................................................................................................................................................................
Tilidine ..............................................................................................................................................................................................
Trimeperidine ...................................................................................................................................................................................
12
12
88
25
12
25
68
53
12
12
10
2
2
2
2
2
12
2
2
2
2
12
12
2
2
2
2
2
2
2
3
12
602
5
12
50
3,990,000
18
67,500,000
25
54
2
5
30
21,000
13
10
14
2
655
12
15
12
12
2
52
2
18
2
2
2
2
10
12
491,000
2
10
2
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
Schedule II
1-Phenylcyclohexylamine ................................................................................................................................................................
1-Piperdinocyclohexanecarbonitrile .................................................................................................................................................
VerDate Mar<15>2010
17:03 Aug 06, 2013
Jkt 229001
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
3g
21 g
48196
Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices
Final adjusted
2013 quotas
Basic class
4-Anilino-N-phenethyl-4-piperidine (ANPP) .....................................................................................................................................
Alfentanil ..........................................................................................................................................................................................
Alphaprodine ....................................................................................................................................................................................
Amobarbital ......................................................................................................................................................................................
Amphetamine (for conversion) ........................................................................................................................................................
Amphetamine (for sale) ...................................................................................................................................................................
Carfentanil ........................................................................................................................................................................................
Cocaine ............................................................................................................................................................................................
Codeine (for conversion) .................................................................................................................................................................
Codeine (for sale) ............................................................................................................................................................................
Dextropropoxyphene ........................................................................................................................................................................
Dihydrocodeine ................................................................................................................................................................................
Diphenoxylate ..................................................................................................................................................................................
Ecgonine ..........................................................................................................................................................................................
Ethylmorphine ..................................................................................................................................................................................
Fentanyl ...........................................................................................................................................................................................
Glutethimide .....................................................................................................................................................................................
Hydrocodone (for sale) ....................................................................................................................................................................
Hydromorphone ...............................................................................................................................................................................
Isomethadone ..................................................................................................................................................................................
Levo-alphacetylmethadol (LAAM) ....................................................................................................................................................
Levomethorphan ..............................................................................................................................................................................
Levorphanol .....................................................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................................
Meperidine .......................................................................................................................................................................................
Meperidine Intermediate-A ..............................................................................................................................................................
Meperidine Intermediate-B ..............................................................................................................................................................
Meperidine Intermediate-C ..............................................................................................................................................................
Metazocine .......................................................................................................................................................................................
Methadone (for sale) .......................................................................................................................................................................
Methadone Intermediate ..................................................................................................................................................................
Methamphetamine ...........................................................................................................................................................................
2,250,000
38,250
3
9
22,875,000
47,186,000
6
240,000
81,250,000
49,506,250
19
250,000
887,500
144,000
3
2,108,750
3
99,625,000
6,750,000
5
4
195
4,500
21,000,000
6,875,000
6
11
6
6
33,125,000
40,500,000
3,912,500
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
[987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,863,750 grams for methamphetamine mostly
for conversion to a schedule III product; and 61,250 grams for methamphetamine (for sale)]
Methylphenidate ...............................................................................................................................................................................
Morphine (for conversion) ................................................................................................................................................................
Morphine (for sale) ..........................................................................................................................................................................
Nabilone ...........................................................................................................................................................................................
Noroxymorphone (for conversion) ...................................................................................................................................................
Noroxymorphone (for sale) ..............................................................................................................................................................
Opium (powder) ...............................................................................................................................................................................
Opium (tincture) ...............................................................................................................................................................................
Oripavine ..........................................................................................................................................................................................
Oxycodone (for conversion) ............................................................................................................................................................
Oxycodone (for sale) .......................................................................................................................................................................
Oxymorphone (for conversion) ........................................................................................................................................................
Oxymorphone (for sale) ...................................................................................................................................................................
Pentobarbital ....................................................................................................................................................................................
Phenazocine ....................................................................................................................................................................................
Phencyclidine ...................................................................................................................................................................................
Phenmetrazine .................................................................................................................................................................................
Phenylacetone .................................................................................................................................................................................
Racemethorphan .............................................................................................................................................................................
Remifentanil .....................................................................................................................................................................................
Secobarbital .....................................................................................................................................................................................
Sufentanil .........................................................................................................................................................................................
Tapentadol .......................................................................................................................................................................................
Thebaine ..........................................................................................................................................................................................
96,750,000
91,250,000
61,125,000
25,628
9,000,000
1,262,500
91,250
1,287,500
22,750,000
10,250,000
153,750,000
18,375,000
7,000,000
42,500,000
6
30
3
42,393,750
3
3,750
215,003
6,880
13,750,000
145,000,000
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
g
15,100,000
4,200,000
44,800,000
6,100,000
246,000,000
g
g
g
g
g
mstockstill on DSK4VPTVN1PROD with NOTICES
List I Chemicals
Ephedrine (for conversion) ..............................................................................................................................................................
Ephedrine (for sale) .........................................................................................................................................................................
Phenylpropanolamine (for conversion) ............................................................................................................................................
Phenylpropanolamine (for sale) .......................................................................................................................................................
Pseudoephedrine (for sale) .............................................................................................................................................................
VerDate Mar<15>2010
17:03 Aug 06, 2013
Jkt 229001
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
E:\FR\FM\07AUN1.SGM
07AUN1
Federal Register / Vol. 78, No. 152 / Wednesday, August 7, 2013 / Notices
Aggregate production quotas for all
other Schedule I and II controlled
substances included in 21 CFR 1308.11
and 1308.12 remain at zero.
Dated: August 1, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013–19046 Filed 8–6–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF LABOR
Employment and Training
Administration
Comment Request for Information
Collection for Job Corps Placement
and Assistance Record, Extension
Without Revisions
Employment and Training
Administration (ETA), Labor.
ACTION: Notice.
AGENCY:
The Department of Labor
(Department), as part of its continuing
effort to reduce paperwork and
respondent burden, conducts a preclearance consultation program to
provide the general public and Federal
agencies with an opportunity to
comment on proposed and/or
continuing collections of information in
accordance with the Paperwork
Reduction Act of 1995 (PRA95) [44
U.S.C. 3506(c)(2)(A)]. This program
helps ensure that requested data can be
provided in the desired format,
reporting burden (time and financial
resources) is minimized, collection
instruments are clearly understood, and
the impact of collection requirements on
respondents can be properly assessed.
Currently, ETA is soliciting comments
concerning the collection of data about
Job Corps Placement Record [OMB
Control No. 1205–0035, expires January
2014]: ETA 678 form, Job Corps
Placement and Assistance Record. ETA
form 678 currently captures information
about a student’s training and
subsequent placement in a job, higher
education or the military, as well as the
name of the placement provider agency.
Data generated from the form ETA 678
is used to evaluate overall placement
outcomes. This form is critical to the
program’s evaluation process. It is the
only form which documents a student’s
post-center placement status. This form
is completed by either a Job Corps
center records staff or a Career
Transition Specialist for each student.
Job Corps is not proposing any changes
to ETA 678 form, Job Corps Placement
Record.
A copy of the proposed Information
Collection Request (ICR) can be
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:03 Aug 06, 2013
Jkt 229001
obtained by contacting the office listed
below in the addressee section of this
notice.
Written comments must be
submitted to the office listed in the
addressee’s section below on or before
October 7, 2013.
ADDRESSES: Submit written comments
to Marcus Gray, Office of Job Corps,
Room N–4463, Employment and
Training Administration, U.S.
Department of Labor, 200 Constitution
Avenue NW., Washington, DC 20210.
Telephone number: 202–693–3967 (this
is not a toll-free number). Individuals
with hearing or speech impairments
may access the telephone number above
via TTY by calling the toll-free Federal
Information Relay Server at 877–889–
5627 (TTY/TDD). Fax: 202–693–2767;
email: gray.marcus@dol.gov. A copy of
the proposed ICR can be obtained by
contacting the person listed above.
SUPPLEMENTARY INFORMATION:
DATES:
I. Background
Job Corps is the nation’s largest
residential, educational, and career
technical training program for young
Americans. Job Corps was established in
1964 by the Economic Opportunity Act,
and currently is authorized by Title I–
C of the Workforce Investment Act of
1998.
For almost 50 years, Job Corps has
helped prepare a total of nearly 3
million at-risk young people ages 16 to
24 for success in our nation’s workforce.
With 125 centers in 48 states, Puerto
Rico, and the District of Columbia, Job
Corps assists students across the nation
in attaining academic credentials,
including a High School Diploma (HSD)
and/or High School Equivalency
credential, and career technical training,
including industry-recognized
credentials, state licensures, and preapprenticeship credentials.
Job Corps is administered by the
Department through the Office of Job
Corps and six Regional Offices. The
Department awards and administers
contracts for the recruiting and
screening of new students, center
operations, and the placement and
transitional support of graduates and
former enrollees. Large and small
corporations and nonprofit
organizations manage and operate 97
Job Corps centers under contractual
agreements with the Department. These
contract Center Operators are selected
through a competitive procurement
process that evaluates potential
operators’ technical expertise, proposed
costs, past performance, and other
factors, in accordance with the
PO 00000
Frm 00063
Fmt 4703
Sfmt 9990
48197
Competition in Contracting Act and the
Federal Acquisition Regulations.
The remaining 28 Job Corps centers,
called Civilian Conservation Centers,
are operated by the U.S. Forest Service,
via an interagency agreement. The
Department has a direct role in the
operation of Job Corps, and does not
serve as a pass-through agency for this
program.
II. Review Focus
The Department is particularly
interested in comments which:
• Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
agency’s function, including whether
the information has practical utility;
• Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
• Enhance the quality, utility, and
clarity of the information to be
collected; and
• Minimize the burden of the
collection of information on those who
are to respond, by encouraging the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology, e.g., permitting
electronic submissions of responses.
III. Current Actions
Type of Review: Extension
Title: Job Corps Placement Record
OMB Number: Control No. 1205–0035
Affected Public: Individuals or
Households (Job Corps students) and
Private Sector—(Job Corps centers)
Form(s): ETA 678
Total Annual Respondents: 34,000
Annual Frequency: Once (when
placement occurs)
Total Annual Responses: 34,000
Average Time per Response: 7.43
minutes
Estimated Total Annual Burden
Hours: 4,210
Total Annual Other Burden Costs for
Respondents: $0
Comments submitted in response to
this comment request will be
summarized and included in the request
for Office of Management and Budget
approval of the information collection
request; they will also become a matter
of public record.
Dated: July 31, 2013.
Eric M. Seleznow,
Acting Assistant Secretary.
[FR Doc. 2013–19061 Filed 8–6–13; 8:45 am]
BILLING CODE 4510–FT–P
E:\FR\FM\07AUN1.SGM
07AUN1
]]>Agencies
[Federal Register Volume 78, Number 152 (Wednesday, August 7, 2013)]
[Notices]
[Pages 48193-48197]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-19046]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-365]
Final Adjusted Aggregate Production Quotas for Schedule I and II
Controlled Substances and Assessment of Annual Needs for the List I
Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2013
AGENCY: Drug Enforcement Administration (DEA), Department of Justice.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This notice establishes final adjusted 2013 aggregate
production quotas for controlled substances in Schedules I and II of
the Controlled Substances Act (CSA) and assessment of annual needs for
the List I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine, as well as the 2013 aggregate production quotas
for three recently temporarily controlled substances.
FOR FURTHER INFORMATION CONTACT: John W. Partridge, Executive
Assistant, Office of Diversion Control, Drug Enforcement
Administration, 8701 Morrissette Drive, Springfield, VA 22152,
Telephone: (202) 307-7165.
SUPPLEMENTARY INFORMATION:
Background
Section 306 of the CSA (21 U.S.C. 826) requires the Attorney
General to establish aggregate production quotas for each basic class
of controlled substance listed in Schedules I and II and for ephedrine,
pseudoephedrine, and phenylpropanolamine. This responsibility has been
delegated to the Administrator of the DEA through 28 CFR 0.100. The
Administrator, in turn, has redelegated this function to the Deputy
Administrator, pursuant to 28 CFR 0.104. DEA published the 2013
established aggregate production quotas for controlled substances in
Schedules I and II and assessment of annual needs for the List I
chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the
Federal Register (77 FR 59980) on October 1, 2012. That notice stated
that the Deputy Administrator would adjust, as needed, the established
aggregate production quotas in 2013 as provided for in 21 CFR 1303.13
and 21 CFR 1315.13. The 2013 proposed adjusted aggregate production
quotas for controlled substances in Schedules I and II and assessment
of annual needs for the List I chemicals ephedrine, pseudoephedrine,
and phenylpropanolamine were subsequently published in the Federal
Register on June 20, 2013, (78 FR 37237) in consideration of the
outlined criteria. All interested persons were invited to comment on or
object to the proposed adjusted aggregate production quotas and
assessment of annual needs on or before July 22, 2013.
Analysis for Final Adjusted 2013 Aggregate Production Quotas and
Assessment of Annual Needs
Consideration has been given to the criteria outlined in the June
20, 2013, notice of proposed adjusted aggregate production quotas and
assessment of annual needs, in accordance with 21 CFR 1303.13 and 21
CFR 1315.13. Six companies submitted timely comments regarding a total
of 30 Schedule I and II controlled substances. Comments received
proposed that the aggregate production quotas for 2-(2,5-Dimethoxy-4-
(n)-propylphenyl)ethanamine (2C-P); 2-(2,5-Dimethoxy-4-
ethylphenyl)ethanamine (2C-E); 2-(2,5-Dimethoxy-4-
methylphenyl)ethanamine (2C-D); 2-(2,5-Dimethoxy-4-nitro-
phenyl)ethanamine (2C-N); 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); 2-
(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine (2C-I); 2-[4-(Ethylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-2); 2-[4-(Isopropylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-4); 3,4-Methylenedioxymethamphetamine
(MDMA); 4-Anilino-N-phenethyl-4-piperidine (ANPP); amphetamine (for
sale); codeine (for conversion); dihydromorphine; diphenoxylate (for
sale); gamma hydroxybutyric acid; hydrocodone; hydromorphone;
levomethorphan; methadone; methadone intermediate; methylphenidate;
morphine (for conversion); morphine (for sale); oxycodone (for sale);
oripavine; oxymorphone (for conversion); oxymorphone (for sale);
phenylacetone; and sufentanil were insufficient to provide for the
estimated medical, scientific, research, and industrial needs of the
United States, for export requirements, and for the establishment and
maintenance of reserve stocks. One manufacturer commented that the APQ
for thebaine was insufficient; however, that commenter was referring to
a need for procurement quota for thebaine, which does not directly
impact the APQ and, thus, was not considered. DEA did not previously
propose adjustments to the 2013 assessment of annual needs for
ephedrine, pseudoephedrine, and phenylpropanolamine and received no
comments concerning such.
DEA has taken into consideration the above comments along with the
relevant 2012 year-end inventories, initial 2013 manufacturing quotas
and import quotas, 2013 export requirements, actual and projected 2013
sales, research and product development requirements, and additional
applications received. Based on all of the above, the Deputy
Administrator has determined that the proposed adjusted 2013 aggregate
production quotas and assessment of annual needs for dihydromorphine;
diphenoxylate (for sale); gamma hydroxybutyric acid; hydromorphone;
levomethorphan; morphine (for sale); oxymorphone (for sale);
phenylacetone; psilocyn; sufentanil; ephedrine (for sale);
phenylpropanolamine (for conversion); and pseudoephedrine (for sale)
required additional consideration and hereby further adjusts the 2013
aggregate production quotas for those substances.
Regarding 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); 2-
(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); 2-(2,5-Dimethoxy-4-
methylphenyl)ethanamine (2C-D); 2-(2,5-Dimethoxy-4-nitro-
phenyl)ethanamine (2C-N); 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
[[Page 48194]]
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); 2-(4-Iodo-2,5-
dimethoxyphenyl)ethanamine (2C-I); 2-[4-(Ethylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-2); 2-[4-(Isopropylthio)-2,5-
dimethoxyphenyl]ethanamine (2C-T-4); 3,4-Methylenedioxymethamphetamine
(MDMA); 4-Anilino-N-phenethyl-4-piperidine (ANPP); amphetamine (for
sale); codeine (for conversion); hydrocodone; methadone; methadone
intermediate; methylphenidate; morphine (for conversion); oxycodone
(for sale); oripavine; and oxymorphone (for conversion), the Deputy
Administrator hereby determines that the proposed adjusted 2013
aggregate production quotas and assessment of annual needs for these
substances and List I chemicals as published on June 20, 2013, (78 FR
37237) are sufficient to meet the current 2013 estimated medical,
scientific, research, and industrial needs of the United States and to
provide for adequate inventories.
As described in the previously published notice establishing the
2013 aggregate production quotas and assessment of annual needs, DEA
has specifically considered that inventory allowances granted to
individual manufacturers may not always result in the availability of
sufficient quantities to maintain an adequate reserve stock pursuant to
21 U.S.C. 826(a), as intended. See 21 CFR 1303.24. This would be
concerning if a natural disaster or other unforeseen event resulted in
substantial disruption to the amount of controlled substances available
to provide for legitimate public need. As such, DEA has included in all
proposed revised Schedule II aggregate production quotas, and certain
Schedule I aggregate production quotas, an additional 25% of the
estimated medical, scientific, and research needs as part of the amount
necessary to ensure the establishment and maintenance of reserve
stocks. The resulting adjusted established aggregate production quotas
will reflect these included amounts. This action will not affect the
ability of manufacturers to maintain inventory allowances as specified
by regulation. DEA expects that maintaining this reserve in certain
established aggregate production quotas will mitigate adverse public
effects if an unforeseen event resulted in substantial disruption to
the amount of controlled substances available to provide for legitimate
public need, as determined by DEA. DEA does not anticipate utilizing
the reserve in the absence of these circumstances.
Pursuant to the above, the Deputy Administrator hereby finalizes
the 2013 aggregate production quotas for the following Schedule I and
II controlled substances and the 2013 assessment of annual needs for
the List I chemicals ephedrine, pseudoephedrine, and
phenylpropanolamine, expressed in grams of anhydrous acid or base, as
follows:
------------------------------------------------------------------------
Final adjusted
Basic class 2013 quotas
------------------------------------------------------------------------
Temporarily Scheduled Substances
------------------------------------------------------------------------
(1-Pentyl-1H-indol-3-yl)(2,2,3,3- 15 g
tetramethylcyclopropyl)methanone (UR-144)............
[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3- 15 g
tetramethylcyclopropyl)methanone (XLR11).............
N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide 15 g
(AKB48)..............................................
------------------------------------------------------------------------
Schedule I
------------------------------------------------------------------------
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)..... 45 g
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694).... 45 g
1-[1-(2-Thienyl)cyclohexyl]piperidine................. 5 g
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH- 45 g
200).................................................
1-Butyl-3-(1-naphthoyl)indole (JWH-073)............... 45 g
1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (SR- 45 g
18 and RCS-8)........................................
1-Hexyl-3-(1-naphthoyl)indole (JWH-019)............... 45 g
1-Methyl-4-phenyl-4-propionoxypiperidine.............. 2 g
1-Pentyl-3-(1-naphthoyl)indole (JWH-018 and AM678).... 45 g
1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)..... 45 g
1-Pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250).... 45 g
1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)..... 45 g
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)..... 45 g
1-Pentyl-3-[(4-methoxy)-benzoyl]indole (SR-19, RCS-4). 45 g
1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole (JWH-081)... 45 g
2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P). 15 g
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E)...... 15 g
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D)..... 15 g
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N)..... 15 g
2-(2,5-Dimethoxyphenyl)ethanamine (2C-H).............. 15 g
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C)..... 15 g
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I)....... 15 g
2,5-Dimethoxy-4-ethylamphetamine (DOET)............... 12 g
2,5-Dimethoxy-4-n-propylthiophenethylamine............ 12 g
2,5-Dimethoxyamphetamine.............................. 12 g
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T- 15 g
2)...................................................
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine 15 g
(2C-T-4).............................................
3,4,5-Trimethoxyamphetamine........................... 12 g
3,4-Methylenedioxyamphetamine (MDA)................... 30 g
3,4-Methylenedioxymethamphetamine (MDMA).............. 50 g
3,4-Methylenedioxy-N-ethylamphetamine (MDEA).......... 24 g
3,4-Methylenedioxy-N-methylcathinone (methylone)...... 35 g
3,4-Methylenedioxypyrovalerone (MDPV)................. 25 g
3-Methylfentanyl...................................... 2 g
3-Methylthiofentanyl.................................. 2 g
[[Page 48195]]
4-Bromo-2,5-dimethoxyamphetamine (DOB)................ 12 g
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)............ 12 g
4-Methoxyamphetamine.................................. 88 g
4-Methyl-2,5-dimethoxyamphetamine (DOM)............... 25 g
4-Methylaminorex...................................... 12 g
4-Methyl-N-methylcathinone (mephedrone)............... 25 g
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 68 g
phenol...............................................
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- 53 g
phenol (cannabicyclohexanol or CP-47, 497 C8-homolog)
5-Methoxy-3,4-methylenedioxyamphetamine............... 12 g
5-Methoxy-N,N-diisopropyltryptamine................... 12 g
5-Methoxy-N,N-dimethyltryptamine...................... 10 g
Acetyl-alpha-methylfentanyl........................... 2 g
Acetyldihydrocodeine.................................. 2 g
Acetylmethadol........................................ 2 g
Allylprodine.......................................... 2 g
Alphacetylmethadol.................................... 2 g
Alpha-ethyltryptamine................................. 12 g
Alphameprodine........................................ 2 g
Alphamethadol......................................... 2 g
Alpha-methylfentanyl.................................. 2 g
Alpha-methylthiofentanyl.............................. 2 g
Alpha-methyltryptamine (AMT).......................... 12 g
Aminorex.............................................. 12 g
Benzylmorphine........................................ 2 g
Betacetylmethadol..................................... 2 g
Beta-hydroxy-3-methylfentanyl......................... 2 g
Beta-hydroxyfentanyl.................................. 2 g
Betameprodine......................................... 2 g
Betamethadol.......................................... 2 g
Betaprodine........................................... 2 g
Bufotenine............................................ 3 g
Cathinone............................................. 12 g
Codeine-N-oxide....................................... 602 g
Desomorphine.......................................... 5 g
Diethyltryptamine..................................... 12 g
Difenoxin............................................. 50 g
Dihydromorphine....................................... 3,990,000 g
Dimethyltryptamine.................................... 18 g
Gamma-hydroxybutyric acid............................. 67,500,000 g
Heroin................................................ 25 g
Hydromorphinol........................................ 54 g
Hydroxypethidine...................................... 2 g
Ibogaine.............................................. 5 g
Lysergic acid diethylamide (LSD)...................... 30 g
Marihuana............................................. 21,000 g
Mescaline............................................. 13 g
Methaqualone.......................................... 10 g
Methcathinone......................................... 14 g
Methyldihydromorphine................................. 2 g
Morphine-N-oxide...................................... 655 g
N,N-Dimethylamphetamine............................... 12 g
N-Benzylpiperazine.................................... 15 g
N-Ethylamphetamine.................................... 12 g
N-Hydroxy-3,4-methylenedioxyamphetamine............... 12 g
Noracymethadol........................................ 2 g
Norlevorphanol........................................ 52 g
Normethadone.......................................... 2 g
Normorphine........................................... 18 g
Para-fluorofentanyl................................... 2 g
Phenomorphan.......................................... 2 g
Pholcodine............................................ 2 g
Properidine........................................... 2 g
Psilocybin............................................ 10 g
Psilocyn.............................................. 12 g
Tetrahydrocannabinols................................. 491,000 g
Thiofentanyl.......................................... 2 g
Tilidine.............................................. 10 g
Trimeperidine......................................... 2 g
------------------------------------------------------------------------
Schedule II
------------------------------------------------------------------------
1-Phenylcyclohexylamine............................... 3 g
1-Piperdinocyclohexanecarbonitrile.................... 21 g
[[Page 48196]]
4-Anilino-N-phenethyl-4-piperidine (ANPP)............. 2,250,000 g
Alfentanil............................................ 38,250 g
Alphaprodine.......................................... 3 g
Amobarbital........................................... 9 g
Amphetamine (for conversion).......................... 22,875,000 g
Amphetamine (for sale)................................ 47,186,000 g
Carfentanil........................................... 6 g
Cocaine............................................... 240,000 g
Codeine (for conversion).............................. 81,250,000 g
Codeine (for sale).................................... 49,506,250 g
Dextropropoxyphene.................................... 19 g
Dihydrocodeine........................................ 250,000 g
Diphenoxylate......................................... 887,500 g
Ecgonine.............................................. 144,000 g
Ethylmorphine......................................... 3 g
Fentanyl.............................................. 2,108,750 g
Glutethimide.......................................... 3 g
Hydrocodone (for sale)................................ 99,625,000 g
Hydromorphone......................................... 6,750,000 g
Isomethadone.......................................... 5 g
Levo-alphacetylmethadol (LAAM)........................ 4 g
Levomethorphan........................................ 195 g
Levorphanol........................................... 4,500 g
Lisdexamfetamine...................................... 21,000,000 g
Meperidine............................................ 6,875,000 g
Meperidine Intermediate-A............................. 6 g
Meperidine Intermediate-B............................. 11 g
Meperidine Intermediate-C............................. 6 g
Metazocine............................................ 6 g
Methadone (for sale).................................. 33,125,000 g
Methadone Intermediate................................ 40,500,000 g
Methamphetamine....................................... 3,912,500 g
------------------------------------------------------------------------
[987,500 grams of levo-desoxyephedrine for use in a non-controlled, non-
prescription product; 2,863,750 grams for methamphetamine mostly for
conversion to a schedule III product; and 61,250 grams for
methamphetamine (for sale)]
------------------------------------------------------------------------
Methylphenidate....................................... 96,750,000 g
Morphine (for conversion)............................. 91,250,000 g
Morphine (for sale)................................... 61,125,000 g
Nabilone.............................................. 25,628 g
Noroxymorphone (for conversion)....................... 9,000,000 g
Noroxymorphone (for sale)............................. 1,262,500 g
Opium (powder)........................................ 91,250 g
Opium (tincture)...................................... 1,287,500 g
Oripavine............................................. 22,750,000 g
Oxycodone (for conversion)............................ 10,250,000 g
Oxycodone (for sale).................................. 153,750,000 g
Oxymorphone (for conversion).......................... 18,375,000 g
Oxymorphone (for sale)................................ 7,000,000 g
Pentobarbital......................................... 42,500,000 g
Phenazocine........................................... 6 g
Phencyclidine......................................... 30 g
Phenmetrazine......................................... 3 g
Phenylacetone......................................... 42,393,750 g
Racemethorphan........................................ 3 g
Remifentanil.......................................... 3,750 g
Secobarbital.......................................... 215,003 g
Sufentanil............................................ 6,880 g
Tapentadol............................................ 13,750,000 g
Thebaine.............................................. 145,000,000 g
------------------------------------------------------------------------
List I Chemicals
------------------------------------------------------------------------
Ephedrine (for conversion)............................ 15,100,000 g
Ephedrine (for sale).................................. 4,200,000 g
Phenylpropanolamine (for conversion).................. 44,800,000 g
Phenylpropanolamine (for sale)........................ 6,100,000 g
Pseudoephedrine (for sale)............................ 246,000,000 g
------------------------------------------------------------------------
[[Page 48197]]
Aggregate production quotas for all other Schedule I and II
controlled substances included in 21 CFR 1308.11 and 1308.12 remain at
zero.
Dated: August 1, 2013.
Thomas M. Harrigan,
Deputy Administrator.
[FR Doc. 2013-19046 Filed 8-6-13; 8:45 am]
BILLING CODE 4410-09-P
